FindTrial
Sign In

Comparison of the effects between ozagrel Na combined with cilostazol and ozagrel Na alone for acute phase ischemic stroke in the territory of perforating arteries of the MCA; a randomized open trial.

Comparison of the effects between ozagrel Na combined with cilostazol and ozagrel Na alone for acute phase ischemic stroke in the territory of perforating arteries of the MCA; a randomized open trial. - Efficacy of cilostazol in the treatment of acute phase ischemic stroke in the territory of perforating arteries of the MCA.

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000296
Enrollment
100
Registered
2005-12-16
Start date
2006-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Patients will be randomly selected to receive combined therapy with ozagrel Na and cilostazol for 14 days. Cilostazol will be administered orally at a daily dose of 200mg. Patients will also be random

Sponsors

Kohnan Hospital Department of Neuroendovascular Therapy
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Initial attack of stroke (2)Beginning of treatment within 48 hours after the onset of symptoms (3)Infarction in the territory of the perforating arteries of the MCA, which should be defined by MR DW image. (4)Informed consent

Exclusion criteria

Exclusion criteria: (1)Occlusive lesion of the internal carotid artery or the middle cerebral artery (2)Hemorrhagic disorders (3)Congestive heart failure (4)Embolic stroke (5)Severe liver and renal dysfunction (6)Malignant disorders (7)Taking cilostazol, ticlipidine , aspirin or warfarin (8)The patient participating in other clinical trials

Design outcomes

Secondary

MeasureTime frame
(1)The frequency of neurological deterioration within 14 days into the treatment. (2)NIHSS at 1 month into the treatment (3)BI at 1 month into the treatment (4)Vascular or other adverse events—

Primary

MeasureTime frame
The frequency of patients with 'minimal or no neurological disability (defined as modified Rankin scale 0-2)' at 1 month into the treatment.—

Countries

Japan

Contacts

Public ContactRyushi Kondoh

Iwate medical university Department of Neurology

rkondoh@iwate-med.ac.jp019-651-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026